◆英語タイトル:Rockwell Medical Inc (RMTI) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8012264
◆発行会社(調査会社):
GlobalData
◆発行日:2017年12月14日
◆ページ数:42
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
※
販売価格オプションの説明はこちらで、
ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※
GlobalData社の概要はこちらでご確認いただけます。
【レポートの概要】
Summary
Rockwell Medical Inc (Rockwell) is a bio pharmaceutical company focusing on the development, manufacture and distribution of products and services for the treatment of iron deficiency, secondary hyperparathyroidism; end-stage renal disease (ESRD) and chronic kidney disease. Its major products include hemodialysis concentrates, dialysis kits and ancillary products used in the dialysis process. The company’s products find applications in the treatment of iron deficiency and secondary hyperparathyroidism; and for hemodialysis. The company markets its products through distributors in the US and through independent sales agents, direct sales force and distributors in overseas markets. RockWell has operations in the US, Latin America, Asia and Europe. Rockwell is headquartered in Wixom, Michigan, the US.
Rockwell Medical Inc (RMTI) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.
Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Rockwell Medical Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Rockwell Medical Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Rockwell Medical Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Rockwell Medical Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Rockwell Medical Inc, Medical Devices Deals, 2011 to YTD 2017 10
Rockwell Medical Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Rockwell Medical Inc, Pharmaceuticals & Healthcare, Deal Details 12
Asset Purchase 12
Rockwell Medical Acquires Generic Drug Calcitriol 12
Licensing Agreements 13
Quimica Europea Enters into Licensing Agreement with Rockwell Medical 13
ARAM Medical Enters into Licensing Agreement with Rockwell Medical 14
Wanbang Biopharma Enters into Licensing Agreement with Rockwell Medical 15
Equity Offering 16
Rockwell Medical Files Registration Statement for Public Offering of Shares for USD200 Million 16
Rockwell Medical Raises USD58.5 Million in Public Offering of Shares 17
Rockwell Medical Raises USD8 Million in Private Placement of Shares upon Exercise of Warrants 19
Rockwell Medical Technologies Completes Public Offering Of Shares For US$40.3 Million 20
Debt Offering 22
Rockwell Medical Completes Private Placement Of Debt Securities For US$20 Million 22
Rockwell Medical Inc – Key Competitors 23
Rockwell Medical Inc – Key Employees 24
Rockwell Medical Inc – Locations And Subsidiaries 25
Head Office 25
Other Locations & Subsidiaries 25
Recent Developments 26
Financial Announcements 26
Nov 08, 2017: Rockwell Medical Announces Third Quarter Results 26
Aug 09, 2017: Rockwell Medical Reports Second Quarter Results 27
May 09, 2017: Rockwell Medical Reports First Quarter Results 28
Mar 15, 2017: Rockwell Medical Reports Fourth Quarter Results 29
Nov 07, 2016: Rockwell Medical Reports Third Quarter Results 30
Aug 08, 2016: Rockwell Medical Reports Second Quarter Results 31
May 10, 2016: Rockwell Medical Reports First Quarter Results 32
Feb 29, 2016: Rockwell Medical Reports Fourth Quarter and Fiscal 2015 Results 33
Corporate Communications 34
Sep 07, 2017: Rockwell Medical Appoints John G. Cooper to Board of Directors 34
Mar 02, 2017: Rockwell Medical Announces Nomination of David Domzalski to Board of Directors 35
Jun 23, 2016: Rockwell Medical Announces Appointment of Dr. Robin Smith to Board of Directors 36
Product News 37
04/28/2016: Rockwell Medical Announces Triferic Presentation “Overcoming Functional Iron Deficiency in Your Hemodialysis Patients” at the National Kidney Foundation (NKF) Spring Clinical Meeting in Boston 37
01/19/2016: Rockwell Medical Announces Two Triferic Poster Presentations Accepted for Presentation at National Kidney Foundation Spring Clinical Meetings April 27 – May 1, 2016 in Boston, MA 38
Product Approvals 39
Apr 26, 2016: U.S. FDA Approves Rockwell Triferic Powder Packet for Treating Anemia in Hemodialysis Patients 39
Mar 21, 2016: China FDA Accepts Rockwell Medical’s Triferic Drug Submission for Commercialization in China 40
Feb 22, 2016: Rockwell Medical Files IND to Investigate Triferic for Rare Orphan Disease Iron-Refractory, Iron-Deficiency Anemia 41
Appendix 42
Methodology 42
About GlobalData 42
Contact Us 42
Disclaimer 42
List of Tables
Rockwell Medical Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Rockwell Medical Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Rockwell Medical Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Rockwell Medical Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Rockwell Medical Inc, Deals By Therapy Area, 2011 to YTD 2017 9
Rockwell Medical Inc, Medical Devices Deals, 2011 to YTD 2017 10
Rockwell Medical Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Rockwell Medical Acquires Generic Drug Calcitriol 12
Quimica Europea Enters into Licensing Agreement with Rockwell Medical 13
ARAM Medical Enters into Licensing Agreement with Rockwell Medical 14
Wanbang Biopharma Enters into Licensing Agreement with Rockwell Medical 15
Rockwell Medical Files Registration Statement for Public Offering of Shares for USD200 Million 16
Rockwell Medical Raises USD58.5 Million in Public Offering of Shares 17
Rockwell Medical Raises USD8 Million in Private Placement of Shares upon Exercise of Warrants 19
Rockwell Medical Technologies Completes Public Offering Of Shares For US$40.3 Million 20
Rockwell Medical Completes Private Placement Of Debt Securities For US$20 Million 22
Rockwell Medical Inc, Key Competitors 23
Rockwell Medical Inc, Key Employees 24
Rockwell Medical Inc, Subsidiaries 25